Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: -0.10 (-5.71%)
Spread: 0.10 (6.25%)
Open: 1.75
High: 1.90
Low: 1.625
Prev. Close: 1.75
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Shield Therapeutics plc

9 May 2023 11:04

Form 8.3 - Shield Therapeutics plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Jupiter Fund Management Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeShield Therapeutics plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held: For an opening position disclosure, state the latest practicable date prior to the disclosure5th May 2023
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1.5p Ordinary
 InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:37,146,9926.34  
(2) Cash-settled derivatives:    
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:37,146,9926.34  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:None
Details, including nature of the rights concerned and relevant percentages:None

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
None   

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
NONE    
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
NONE       

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
NONE    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
None   

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:9th May 2023
Contact name:Jon Watson
Telephone number:0203 817 1672

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
30th Apr 20247:00 amRNSBusiness Update for Q1 2024
16th Apr 20247:00 amRNSNotice of Results
21st Feb 20247:00 amRNSUnaudited Full Year Trading Update
9th Jan 20247:00 amRNSAppointment of new Chief Financial Officer
7th Dec 20237:00 amRNSQ3 2023 U.S. Commercial Highlights
27th Nov 20235:24 pmRNSPDMR Transaction Notification
15th Nov 20237:30 amEQSHardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
20th Oct 202311:45 amRNSAbstract to be presented at Healthcare Conference
12th Oct 20237:00 amRNSChief Financial Officer Transition
3rd Oct 20233:00 pmRNSResult of REX Retail Offer
3rd Oct 20237:00 amRNSBlock listing Interim Return
3rd Oct 20237:00 amRNSCompletion of SWK Financing
28th Sep 202312:50 pmRNSSuccessful completion of US$6.1m Equity Fundraise
28th Sep 20237:02 amRNSREX Retail Offer
28th Sep 20237:01 amRNS$20m secured debt facility &proposed equity raise
28th Sep 20237:00 amRNSInterim results update and business update
6th Sep 20237:00 amRNSNotice of Results and Change in reporting currency
25th Jul 20239:45 amEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
24th Jul 20232:27 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSBusiness Update and U.S. Q2 2023 Highlights
28th Jun 20235:30 pmRNSResults of 2023 Annual General Meeting
16th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
15th Jun 20234:35 pmRNSLapse of Offer
15th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
15th Jun 20237:00 amRNSAcceptance Level Update
14th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
14th Jun 20237:00 amRNSAcceptance Level Update
13th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
13th Jun 20237:00 amRNSAcceptance Level Update
12th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th Jun 20237:00 amRNSAcceptance Level Update
9th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th Jun 20237:00 amRNSAcceptance Level Update
8th Jun 202312:31 pmRNSForm 8.3 - Shield Therapeutics PLC (amendment)
8th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
8th Jun 20237:00 amRNSAcceptance Level Update
7th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
6th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
6th Jun 202310:10 amRNSGrant of share options to the CEO
5th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
2nd Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
1st Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
1st Jun 202311:00 amRNSHolding(s) in Company
1st Jun 202310:55 amRNSHolding(s) in Company
31st May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
31st May 20237:00 amRNSTotal Voting Rights
30th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
26th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
25th May 20234:44 pmRNSPublication and posting of Offer Document
25th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.